Table 5

SLE disease characteristics for patients with SLE treated with RTX and conventional IS

RTXNISNp Value
Disease duration years, mean±SD9.1±7.11014.1±6.672<0.0001
Organ manifestation(%)103(%)72
Renal (LN)5853NS
Musculoskeletal11220.038
Haematological1511NS
Skin66NS
CNS73NS
Other35NS
Reason for treatment(%)103(%)72
Controlling disease7744<0.0001
Steroid-sparing114<0.0001
Both22420.006
Disease activity
SLEDAI, mean±SD12.2±7.11029.4±7.0720.010
SLICC-DI, mean±SD1.6±3.4960.6±1.0720.014
SLEDAI, LN vs
non-LN*
14.6±6.2 vs
9.0±6.9
59
43
12.5±7.6 vs
5.9±4.3
38
34
<0.0001
(within groups treatments)
  • *SLEDAI between groups, treatments: LN, NS; non-LN p=0.029.

  • CNS, central nervous system; IS, immunosuppressive; LN, lupus nephritis; NS, not significant; RTX, rituximab; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.